Financhill
Sell
22

CVM Quote, Financials, Valuation and Earnings

Last price:
$0.28
Seasonality move :
15.75%
Day range:
$0.30 - $0.32
52-week range:
$0.29 - $2.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.08x
Volume:
583.4K
Avg. volume:
1M
1-year change:
-85.59%
Market cap:
$23.5M
Revenue:
--
EPS (TTM):
-$0.48

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CVM
CEL-SCI
-- -- -- -- $7.40
AIM
AIM ImmunoTech
$100K -$0.09 -23.08% -53.85% $2.75
IGC
IGC Pharma
$204K -$0.03 3.39% -50% $3.88
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
PLX
Protalix BioTherapeutics
$18.7M -- 476.31% -- $14.50
PTN
Palatin Technologies
-- -$0.42 -100% -67.93% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CVM
CEL-SCI
$0.30 $7.40 $23.5M -- $0.00 0% --
AIM
AIM ImmunoTech
$0.12 $2.75 $7.4M -- $0.00 0% 31.88x
IGC
IGC Pharma
$0.33 $3.88 $26.7M -- $0.00 0% 19.69x
NBY
NovaBay Pharmaceuticals
$0.63 $0.85 $3.1M -- $0.00 0% 0.07x
PLX
Protalix BioTherapeutics
$2.24 $14.50 $164.9M 121.00x $0.00 0% 3.85x
PTN
Palatin Technologies
$0.79 $7.00 $20.6M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CVM
CEL-SCI
-- 1.534 -- --
AIM
AIM ImmunoTech
48.41% 1.568 17.25% 0.71x
IGC
IGC Pharma
2.1% -1.752 0.51% 0.21x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
PLX
Protalix BioTherapeutics
-- 1.969 -- 1.22x
PTN
Palatin Technologies
-- -1.737 -- 0.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CVM
CEL-SCI
-- -$6.9M -- -- -- -$4.2M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
IGC
IGC Pharma
$104K -$1.9M -114.2% -116.24% -730.74% -$1.4M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PLX
Protalix BioTherapeutics
$9.6M $4M -19.69% -29.54% 23.06% $4M
PTN
Palatin Technologies
-- -$5.1M -- -- -2356.3% -$4.8M

CEL-SCI vs. Competitors

  • Which has Higher Returns CVM or AIM?

    AIM ImmunoTech has a net margin of -- compared to CEL-SCI's net margin of -10571.43%. CEL-SCI's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    CVM
    CEL-SCI
    -- -$0.11 --
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About CVM or AIM?

    CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 2270.69%. Given that CEL-SCI has higher upside potential than AIM ImmunoTech, analysts believe CEL-SCI is more attractive than AIM ImmunoTech.

    Company Buy Ratings Hold Ratings Sell Ratings
    CVM
    CEL-SCI
    1 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is CVM or AIM More Risky?

    CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.411, suggesting its less volatile than the S&P 500 by 58.887%.

  • Which is a Better Dividend Stock CVM or AIM?

    CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CVM or AIM?

    CEL-SCI quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. CEL-SCI's net income of -$7.1M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, CEL-SCI's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 31.88x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CVM
    CEL-SCI
    -- -- -- -$7.1M
    AIM
    AIM ImmunoTech
    31.88x -- $35K -$3.7M
  • Which has Higher Returns CVM or IGC?

    IGC Pharma has a net margin of -- compared to CEL-SCI's net margin of -711.67%. CEL-SCI's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    CVM
    CEL-SCI
    -- -$0.11 --
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
  • What do Analysts Say About CVM or IGC?

    CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1057.41%. Given that CEL-SCI has higher upside potential than IGC Pharma, analysts believe CEL-SCI is more attractive than IGC Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    CVM
    CEL-SCI
    1 0 0
    IGC
    IGC Pharma
    2 0 0
  • Is CVM or IGC More Risky?

    CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.346%.

  • Which is a Better Dividend Stock CVM or IGC?

    CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CVM or IGC?

    CEL-SCI quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. CEL-SCI's net income of -$7.1M is lower than IGC Pharma's net income of -$1.8M. Notably, CEL-SCI's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 19.69x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CVM
    CEL-SCI
    -- -- -- -$7.1M
    IGC
    IGC Pharma
    19.69x -- $257K -$1.8M
  • Which has Higher Returns CVM or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to CEL-SCI's net margin of -49.65%. CEL-SCI's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    CVM
    CEL-SCI
    -- -$0.11 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About CVM or NBY?

    CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 34.9%. Given that CEL-SCI has higher upside potential than NovaBay Pharmaceuticals, analysts believe CEL-SCI is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CVM
    CEL-SCI
    1 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is CVM or NBY More Risky?

    CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock CVM or NBY?

    CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CVM or NBY?

    CEL-SCI quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. CEL-SCI's net income of -$7.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, CEL-SCI's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CVM
    CEL-SCI
    -- -- -- -$7.1M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns CVM or PLX?

    Protalix BioTherapeutics has a net margin of -- compared to CEL-SCI's net margin of 18.02%. CEL-SCI's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

    Company Gross Margin Earnings Per Share Invested Capital
    CVM
    CEL-SCI
    -- -$0.11 --
    PLX
    Protalix BioTherapeutics
    53.37% $0.03 $32.4M
  • What do Analysts Say About CVM or PLX?

    CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 547.32%. Given that CEL-SCI has higher upside potential than Protalix BioTherapeutics, analysts believe CEL-SCI is more attractive than Protalix BioTherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CVM
    CEL-SCI
    1 0 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is CVM or PLX More Risky?

    CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.611%.

  • Which is a Better Dividend Stock CVM or PLX?

    CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CVM or PLX?

    CEL-SCI quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. CEL-SCI's net income of -$7.1M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, CEL-SCI's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 3.85x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CVM
    CEL-SCI
    -- -- -- -$7.1M
    PLX
    Protalix BioTherapeutics
    3.85x 121.00x $18M $3.2M
  • Which has Higher Returns CVM or PTN?

    Palatin Technologies has a net margin of -- compared to CEL-SCI's net margin of -2357.27%. CEL-SCI's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CVM
    CEL-SCI
    -- -$0.11 --
    PTN
    Palatin Technologies
    -- -$0.12 -$111.5K
  • What do Analysts Say About CVM or PTN?

    CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 785.18%. Given that CEL-SCI has higher upside potential than Palatin Technologies, analysts believe CEL-SCI is more attractive than Palatin Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    CVM
    CEL-SCI
    1 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is CVM or PTN More Risky?

    CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

  • Which is a Better Dividend Stock CVM or PTN?

    CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CVM or PTN?

    CEL-SCI quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. CEL-SCI's net income of -$7.1M is lower than Palatin Technologies's net income of -$2.4M. Notably, CEL-SCI's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CVM
    CEL-SCI
    -- -- -- -$7.1M
    PTN
    Palatin Technologies
    -- -- $350K -$2.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
49
SMTC alert for Mar 17

Semtech [SMTC] is down 0.49% over the past day.

Buy
62
PLPC alert for Mar 17

Preformed Line Products [PLPC] is up 3.8% over the past day.

Sell
50
NUTX alert for Mar 17

Nutex Health [NUTX] is up 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock